High IL2RA/CD25 expression is a prognostic stem cell biomarker for pediatric acute myeloid leukemia without a core-binding factor

被引：3

作者：

Aoki, Takahiro ^{[1
,18
]}

Shiba, Norio ^{[2
]}

Tsujimoto, Shinichi ^{[2
]}

Yamato, Genki ^{[3
]}

Hara, Yusuke ^{[3
]}

Kato, Shota ^{[4
]}

Yoshida, Kenichi ^{[5
]}

Ogawa, Seishi ^{[6
,7
,8
]}

Hayashi, Yasuhide ^{[9
]}

Iwamoto, Shotaro ^{[10
]}

Taki, Tomohiko ^{[11
]}

Shimada, Akira ^{[12
]}

Iijima-Yamashita, Yuka ^{[13
]}

Horibe, Keizo ^{[13
]}

Tawa, Akio ^{[14
]}

Taga, Takashi ^{[15
]}

Adachi, Souichi ^{[16
]}

Tomizawa, Daisuke ^{[17
]}

机构：

[1] Chiba Univ, Grad Sch Med, Dept Pediat, Chiba, Japan

[2] Yokohama City Univ, Grad Sch Med, Dept Pediat, Yokohama, Japan

[3] Gunma Univ, Grad Sch Med, Dept Pediat, Maebashi, Japan

[4] Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo, Japan

[5] Natl Canc Ctr, Div Canc Evolut, Tokyo, Japan

[6] Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Kyoto, Japan

[7] Kyoto Univ, Inst Adv Study Human Biol WPI ASHBi, Kyoto, Japan

[8] Karolinska Inst, Ctr Hematol & Regenerat Med, Dept Med, Stockholm, Sweden

[9] Jobu Univ, Inst Physiol & Med, Takasaki, Japan

[10] Mie Univ, Dept Pediat, Tsu, Japan

[11] Kyorin Univ, Fac Hlth Sci, Dept Med Technol, Mitaka, Japan

[12] Jichi Med Univ, Dept Pediat, Shimotsuke, Japan

[13] NHO Nagoya Med Ctr, Clin Res Ctr, Nagoya, Japan

[14] Higashiosaka Aramoto Heiwa Clin, Higashiosaka, Japan

[15] Shiga Univ Med Sci, Dept Pediat, Shiga, Japan

[16] Kyoto Univ, Dept Human Hlth Sci, Kyoto, Japan

[17] Natl Ctr Child Hlth & Dev, Childrens Canc Ctr, Div Leukemia & Lymphoma, Tokyo, Japan

[18] Chiba Univ, Grad Sch Med, Dept Pediat, 1 8 1 Inohana,Chuo Ku, Chiba 2608670, Japan

来源：

PEDIATRIC BLOOD & CANCER | 2024年 / 71卷 / 02期

基金：

日本学术振兴会;

关键词：

acute myeloid leukemia; CD25; children; leukemic stem cells; RNA sequencing; CD25; EXPRESSION; FAILURE; RELAPSE; TRIAL;

D O I：

10.1002/pbc.30803

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CD25 is an aberrant marker expressed on the leukemic stem cell (LSC) surface and an immunotherapy target in acute myeloid leukemia (AML). However, the clinical prevalence and significance of CD25 expression in pediatric AML are unknown. High IL2RA/CD25 expression in pediatric AML showed a stem cell-like phenotype, and elevated CD25 expression was associated with lower overall survival (p < .001) and event-free survival (p < .001) in the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study. This finding was reproduced in AML without a core-binding factor in the Children's Oncology Group study cohort. High CD25 expression has prognostic significance in pediatric AML.

引用

页数：5

共 50 条

[31] IL-2/CD25 axis mediates cellular networks promoting the growth of CD25+ acute myeloid leukemia cells
Nakase, Kazunori
Kita, Kenkichi
LEUKEMIA RESEARCH REPORTS, 2024, 21
[32] KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor
Kohl, TM
Schnittger, S
Ellwart, JW
Hiddemann, W
Spiekermann, K
BLOOD, 2005, 105 (08) : 3319 - 3321
[33] Expression of CD25 on Acute Myeloid Leukemia (AML) Blasts Is An Independent Risk Factor Associated with Refractory Disease, Which May Be Overcome by Stem Cell Transplantation (SCT)
Cerny, Jan
Woods, Lesley
Yu, Hongbo
Ramanathan, Muthalagu
Raffel, Glen D.
Walsh, William V.
Petrillo-Deluca, Laura J.
Tarrasky, Natasha M.
O'Rourke, Elizabeth
Bednarik, Jayde L.
Woda, Bruce
Hutchinson, Lloyd
Kroll, Aimee
Barton, Bruce
Rosmarin, Alan G.
Nath, Rajneesh
BLOOD, 2011, 118 (21) : 1519 - 1519
[34] Prognostic Relevance of Cytokine Receptor Expression in Acute Myeloid Leukemia: Interleukin-2 Receptor α-Chain (CD25) Expression Predicts a Poor Prognosis
Nakase, Kazunori
Kita, Kenkichi
Kyo, Taiichi
Ueda, Takanori
Tanaka, Isao
Katayama, Naoyuki
PLOS ONE, 2015, 10 (09):
[35] PRDM1 decreases sensitivity of human NK cells to IL2-induced cell expansion by directly repressing CD25 (IL2RA)
Akman, Burcu
Hu, Xiaozhou
Liu, Xuxiang
Hatipoglu, Tevfik
You, Hua
Chan, Wing C.
Kucuk, Can
JOURNAL OF LEUKOCYTE BIOLOGY, 2021, 109 (05) : 901 - 914
[36] Clinical impact of CD25 expression on outcomes of allogeneic hematopoietic stem cell transplant for cytogenetically intermediate-risk acute myeloid leukemia
Ikegawa, Shuntaro
Doki, Noriko
Yamamoto, Keita
Shingai, Naoki
Takahashi, Yukie
Aoki, Jun
Yoshioka, Kosuke
Narukawa, Kensuke
Ishida, Shinya
Igarashi, Aiko
Oshikawa, Gaku
Kobayashi, Takeshi
Kakihana, Kazuhiko
Sakamaki, Hisashi
Haraguchi, Kyoko
Okuyama, Yoshiki
Ohashi, Kazuteru
LEUKEMIA & LYMPHOMA, 2015, 56 (06) : 1874 - 1877
[37] Oncogenic over-expression of MED12 is epigenetically fostered in the core-binding factor subgroups of acute myeloid leukemia
Choudhury, Samrat Roy
Bhattacharya, Arkajyoti
CANCER RESEARCH, 2023, 83 (07)
[38] High rate of durable remissions post autologous stem cell transplantation for core-binding factor acute myeloid leukaemia in second complete remission
Rees, Matthew J.
Spencer, Andrew
Browett, Peter
Alvaro, Frank
Purtill, Duncan
Crawford, Julie
Milliken, Sam
Lai, Hock
Pullon, Humphrey
Grigg, Andrew
BONE MARROW TRANSPLANTATION, 2020, 55 (11) : 2207 - 2210
[39] Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations
E Manara
V Bisio
R Masetti
V Beqiri
R Rondelli
G Menna
C Micalizzi
N Santoro
F Locatelli
G Basso
M Pigazzi
Leukemia, 2014, 28 : 1132 - 1134
[40] Influence of KIT mutations on prognosis of pediatric patients with core-binding factor acute myeloid leukemia: a systematic review and meta-analysis
Fan, Junjie
Gao, Li
Chen, Jing
Hu, Shaoyan
TRANSLATIONAL PEDIATRICS, 2020, 9 (06) : 726 - 733

← 1 2 3 4 5 →